(Boursier.com) — THE TREND
This very start of the year will have been marked by a correction in the stock market indices after their good end to the 2023 financial year, in particular the American Nasdaq which has already lost more than 3% in three sessions… The CAC40, which was a little recovered yesterday fell again this Friday by 0.40% to 7,420 points, after falling to a low of 7,350 points during the session.
The annual inflation rate in the euro zone stood at 2.9% in December, compared to 2.4% the previous month according to preliminary data from Eurostat. The markets are also still worried about the risks of armed escalation in the Middle East. Enough to keep oil above $78 per barrel for Brent…
In the United States, according to the American Department of Labor, non-agricultural job creations for the month of December 2023 stood at 216,000, well above the consensus which was only 160,000. The unemployment rate stood at 3.7% against a consensus of 3.8%. The average hourly wage increased by 0.4% compared to the previous month against 0.3% consensus. The labor force participation rate was 62.5%. Job creations in the private sector totaled 164,000, compared to 130,000 consensus and 136,000 for the revised reading of the previous month. Total job creations for November were posted at 173,000 in revised reading against 199,000 previously estimated…
The euro was stable at 1.0950/$ following these announcements.
RISING VALUES
Abionyx : +3% followed by TFF
Vallourec : +2% with BigBen, Euroapi (+1.5%)
Score : +1.5% with DBV, TF1, Nokia, Essilor and Forvia
Renault : +1% followed by Exail, Vivendi and Engie
The medical research society MedinCell advances 1% after a jump of more than 8% on Thursday. Jefferies initiated monitoring of the stock with a ‘buy’ rating and a price target of 12 euros, representing a potential appreciation of +74% compared to Wednesday’s closing price. The analyst considers Medincell to be the best positioned player in the field of long-acting injectable products thanks to its advanced drug delivery technology which should allow it to outperform its competitors in indications where the medical need is high and growing…
FALLING VALUES
Remy Cointreau collapses by more than 12% to less than 96 euros after having already lost more than 5% over the last three days. The selling pressure on the spirits group, which has been at its lowest level since May 2020, is linked to information from China to the extent that the Chinese Ministry of Commerce announced the launch of an anti-competitive investigation into spirits. -life of wine, such as cognac, imported from the European Union. The investigation by Chinese authorities followed a complaint from the China Alcoholic Beverage Association on behalf of the local wine spirits industry, the ministry said.
Pernod Ricardalthough less exposed to wine spirits, drop of 3.5%.
Rally fell by 11% followed by AB Science (-6%) with Casino, Waga (-4%) and Genfit
LNA Health loses 3.5% with Prodways, Coty and Ubisoft (-3%)
Clariane : -2.5% with Aubay, Innate, Getlink, LDC and Sopra Steria
Capgemini : -1.5% followed by Sword and Virbac with Equasens
Schneider Electric lost 1.1% to 171.6 euros, while the stock is among the strongest gains in a year (+25%). Among the latest broker opinions, Morgan Stanley remains at ‘market weighting’ on the group with a target raised from 155 to 168 euros.